The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | A cost per responder analysis of cilta-cel vs physician’s choice in lenalidomide-refractory MM
Doris Hansen, MD, Moffitt Cancer Center, Tampa, FL, presents the findings of a cost per responder (CPR) analysis of patients with relapsed and lenalidomide-refractory multiple myeloma (MM) enrolled in the CARTITUDE-4 trial (NCT04181827), comparing ciltacabtagene autoleucel (cilta-cel) to pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd). This analysis highlighted that the costs per complete responder and per month in progression-free survival (PFS) were substantially lower when treating patients with cilta-cel; an important factor for physicians to consider when choosing between cilta-cel, PVd, or DPd. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Bristol Myers Squibb, Karyopharm, Janssen, Pfizer; Membership on an entity’s Board of Directors or advisory committees: Bristol Myers Squibb, Pfizer; Research Funding: Bristol Myers Squibb, Karyopharm, International Myeloma Society Young Investigator Award, Pentecost Family Myeloma Research Center; Honoraria: OncLive, Survivorship
